key: cord-0943969-tz5p4m1p authors: Burbury, Kate; Wong, Zee‐Wan; Yip, Desmond; Thomas, Huw; Brooks, Peter; Gilham, Leslie; Piper, Amanda; Solo, Ilana; Underhill, Craig title: Telehealth in cancer care: during and beyond the COVID‐19 pandemic date: 2021-02-11 journal: Intern Med J DOI: 10.1111/imj.15039 sha: aedd8d2263a28dfe81ab87e976c6ab710aae66d7 doc_id: 943969 cord_uid: tz5p4m1p The COVID‐19 pandemic has precipitated the rapid uptake of telehealth in cancer care and in other fields. Many of the changes made in routine clinical practice could be embedded beyond the duration of the pandemic. This is intended as a practical guide to cancer clinicians and others in establishing and improving the quality of consultations performed by telehealth. With the need for physical distancing and reduction of foot traffic through healthcare institutions, deployment of telehealth (TH) into routine care during the COVID-19 pandemic has demonstrated benefits for patients and clinicians. We need to remain motivated to continue this modality and this document provides insights and practical considerations to support this. A fundamental priority is maintaining high quality cancer care for all patients. Local architectural (infrastructure, resources and personnel), social and geographical constraints, creates access and quality differentials. [1] [2] [3] [4] Particularly among those most vulnerable, such as those from regional/rural areas as well as cultural, social and linguistically diverse. Digital tools provide solution strategies to overcome logistical challenges that contribute to the disparities. TH has enabled this during social restrictions and can be used for all mediums of care delivery, such as outpatient, pre-therapy reviews, pre-habilitation programmes, preparation for surgery, acute and late effects monitoring, chemotherapy and systemic treatment delivery ('telechemotherapy') and conduct of clinical trials ('teletrials'). 5−7 The COVID-19 pandemic response has demonstrated that healthcare providers and patients are willing to embrace TH. The most important benefits are to patients and their families: reduced travel and social disruptions, financial savings, enhanced chronic care delivery and creating safe healthcare environments. Traditional referral strategies usually adhere to the nearest available provider; however, telehealth and digital tools enable specialists at a greater distance to help provide services to regions that may not have local specialists, care models and/or specialist services. Equally, an important outcome of TH is the synchronous partnering with the local healthcare team when delivering care, enabling continuity and shared care arrangements for patients returning to their local areas after being treated at metropolitan services. TH provides efficient and flexible service delivery, enabling clinicians to maintain involvement, independent of their physical location. The broader strategy of enabling 'synchronous' partnerships with regional or remote areas and their expert metropolitan counterparts, will provide professional opportunities for regional or rural specialists to help advance the science and practice of healthcare Australia wide. There are some potential limitations with TH, compared to face-to-face (F2F) consultations. 7 Communication can be impacted if sound or vison quality is poor, due to internet connectivity or bandwidth. It can be more difficult to establish rapport during a new patient consultation or when breaking difficult news. Where physical examination is indicated, assistance at the patient's site to conduct a full physical examination, such as in partnership with a general practitioner or specialist nurse, can be required. However, there are also many upsides. The purpose of this article is to provide insights and practical solutions, with regards to the enablers and challengers of maintaining TH as part of routine care for our patients going forward, including guidance across tumour streams, given the demonstrable patients, their families, clinicians, healthcare institutions and society. Rapid support from Commonwealth funding during COVID-19, including temporary new Medicare item numbers, has enabled the widespread uptake. This has exposed the opportunity and the benefits. Advocacy by expert groups and patients will need to lobby to extend funding with a more generous scope than previously. The information and communication technology should be fit for purpose. Reliable equipment that works well over the available network and bandwidth, is secure with privacy and confidentiality ensured, compatible between clinician and patient, and facilitates good communication and accurate transfer of information. COVIU or Health Direct is set up to manage a significant increase in video calls and is favoured in the opinion of the authors over Skype, Zoom, Facetime, WhatsApp or other collaborative tools for IT, billing and security/privacy reasons. Comparisons between platforms are detailed in Table 1 . Other advantages of Health Direct include: • TH is no different from any medical consultation and should be conducted exactly as you would F2F with engagement of the patient, thorough assessment and review, further recommendations for assessment, clarification of diagnosis and recommendations for treatment. • TH does not need to be used exclusively, but rather as an adjunct to maintain continuity of care (e.g. alternate visits F2F and TH). • TH consultations should maintain the patient's privacy and confidentiality at all times, with processes in place to facilitate this as per standard F2F consultations. Not all consultations may be suitable for TH. Key principles to be considered include: 1 It is fundamental that the patient/carer or family member are able and willing to participate Allowing the patient to be in their 'own' preferred environment, rather than the formal clinic, can provide a greater degree of comfort in the conversation and more likely to divulge the required information to assess needs. This can be particularly relevant for psychosocial needs, culturally and linguistically diverse communities 2 Clinical factors: Consideration of scheduled investigations on the same day of review, need for comprehensive clinical examination (see below), using TH to provide an opportunity for enhanced continuity and shared care with local providers to travel, including family, work, SES, cultural situation; patient capacity, vision and hearing impairments require consideration. If patients are undergoing more intensive or new therapies, with the possibility of emergent side-effects or toxicity, TH allows more frequent reviews mitigating extra travel and commitment to attend in person. This holds true for any clinical situation requiring frequent reviews. Specific consideration for tumour subgroups is outlined in Table 2 . A common concern regarding TH is the need for clinical examination; these strategies can enhance the process: 1 Include local healthcare providers who can assist with the clinical examination and provide the environment for care continuity 2 Without the local healthcare provider (i.e. patient only) a Preparation: Prior knowledge of patient's history and examination, access to medical records b Adequate lighting, free from background noise and disturbances to enhance the virtual assessment c Additional questions to draw out physical changes that may not be apparent (compared with F2F) d Remote monitoring tools can be used to supplement this e Where an examination is required during the consultation, the patient can attend local healthcare provider for further assessment or to attend clinic in person Practical tips for the clinician during the consultation 1. An appropriate device: smartphone or tablet; Home computer or laptop with a webcam/microphone/speaker (with Chrome installed). 2. Access to TH software platform, with secure log-in. 3. Resources to enable clinician and patient: a. Instructions to the patient, outlining their upcoming appointment b. E-forms for requesting investigations 4. Patient flow mapping As with all in-person appointments, patient flow through the consultation needs to be mapped and enabled: a Instructions to patients when booking appointments, capture of key patient information including clinical and supportive care requirements b Patient check-into alert the clinician they are in the virtual waiting room c Post clinic activity capture -including billing items and next follow-up appointments pre-next review i Pathology: scan and email or post to patient ii Radiology: scan and email or post to patient or radiology provider iii Referrals to other specialists or providers iv Prescriptions v Documentation of the review in the medical record and correspondence to appropriate healthcare providers 5 Prescription a COVID 19 emergency provisions have allowed e-prescriptions, original being retained for 2 years b Most pharmacies will honour a scan or photo prescription, but require the original c Specifically, schedule 4 or 8 medicines require verbal confirmation with the pharmacy Finally, an important outcome will be the delivery of clinical trials via the Tele-Trial Model. 8-10 Cancer Council Victoria data has shown that <5% of patients from regional/rural Victoria participate in trials due to the same logistic challenges (Underhill, pers. comm.). The VCCC teletrials programme has facilitated the conduct of three trials across seven sites in metropolitan and regional Victoria. In addition, a phase 1 study is being conducted by TH between a Victorian and an interstate site. A fourth study has opened, and several others are in start-up. More than 80 patients from regional Victoria have been recruited to the three clinical trials. In 2017, only 81 cancer patients in regional Victoria were recruited to studies, so this represents a considerable improvement in recruitment and access to trials for regional patients. Successful clinical trial conduct, which facilitates advancement in science and healthcare delivery, has geographical constraints; challenges around variable regulatory arrangements across jurisdictions; slow patient recruitment processes and timelines, which are cost prohibitive, lead to trial closure, and reduce potential access to trial programs. The ability to participate in trials closer to home will reduce burden and costs and enhance patient recruitment and retention. The tele-trial model will overcome major barriers to trial conduct; provide equity of access to patients; invest personnel, infrastructure and resources in regional/rural centres; and help advance the science and practice of cancer care Australia-wide. The rapid adoption of TH across all cancer services within Victoria during COVID-19 pandemic surfaced significant barriers to implementation of telehealth via video consultation. The top major barriers through a survey were infrastructure, IT and organisation support as well as patient literacy. 11 However, the COVID-19 pandemic response has demonstrated that healthcare providers and patients are willing to embrace digital tools to maintain and continue high quality care delivery. Areas that require ongoing effort are enabling different health systems to freely and safely share data, allowing patients to receive care at any time and place. Government investment and support of infrastructure and resources to support deployment of digital health will be required, including connectivity and access for remote areas, elderly and vulnerable patients. In addition, harmonisation of government policy and the regulatory environment for widespread adoption of systematic and best clinical care models and the teletrial model for trial access is needed. Embedding telehealth into cancer care is likely to result in improved outcomes, especially for regional and other disadvantaged populations. Internal Medicine Journal 51 (2021) 125-133 model-final-19sep16.pdf Pharmacy Fact Sheet. National Health Plan. A Guide for Pharmacists 19-national-health-plan-prescriptions-viatelehealth-a-guide-for-pharmacists.pdf COVID-19 National Health Plan -prescriptions via telehealth -a guide for prescribers Victorian Department of Health and Human Services Australian Government Cancer Australia. Cancer Australia Strategic Plan 2014-2019. Sydney: Cancer Australia Australia is continuing to make progress against cancer, but the regional and remote disadvantage remains Cancer health inequality persists in regional and remote Australia A National Telehealth Strategy For Australia -For Discussion. Australian National Consultative Committee on Electronic Health (ANCCEH) Enhancing chemotherapy capabilities in rural hospitals: implementation of a telechemotherapy model Impact of COVID-19 on oncology clinical trials Telehealth in cancer care during the COVID-19 pandemic Teletrials: implementation of a new paradigm for clinical trials